Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00595543 · ClinicalTrials.gov registry record · Phase 4
Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%
A Phase 4 study of Acute Pseudophakic Cystoid Macular Edema, sponsored by Bp Consulting.
- Completed
- Registry status
- Phase 4
- Development phase
- 166
- Enrollment target
- 1
- Study location
NCT00595543 is a Phase 4 study of Acute Pseudophakic Cystoid Macular Edema that has completed, run by Bp Consulting. The registered enrollment target is 166 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00595543, a Phase 4 study of Acute Pseudophakic Cystoid Macular Edema, has completed, sponsored by Bp Consulting.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 166 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare bromfenac 0.09%, diclofenac sodium 0.1%, and ketorolac tromethamine 0.5% ophthalmic solutions for the treatment of acute pseudophakic CME after cataract surgery.
Conditions Studied
Interventions
- DRUG Ketorolac
- DRUG Diclofenac
- DRUG Bromfenac
Study Locations (1)
Pennsylvania
- Soll Eye Associates - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00595543
The ClinicalTrials.gov registry entry for NCT00595543 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bp Consulting, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Pseudophakic Cystoid Macular Edema appearing as the primary indexed condition, and to 3 interventions - of which Ketorolac is the first listed.
NCT00595543 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00595543 about?
NCT00595543 is a clinical study titled "Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%". To compare bromfenac 0.09%, diclofenac sodium 0.1%, and ketorolac tromethamine 0.5% ophthalmic solutions for the treatment of acute pseudophakic CME after cataract surgery.
What is the current status of trial NCT00595543?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 166 participants. The study started on 2008-01. Estimated completion is 2009-03.
What conditions does trial NCT00595543 study?
This clinical trial studies the following conditions: Acute Pseudophakic Cystoid Macular Edema.
What interventions are being tested in trial NCT00595543?
The interventions under investigation include: Ketorolac (DRUG), Diclofenac (DRUG), Bromfenac (DRUG).
Who is sponsoring clinical trial NCT00595543?
This trial is sponsored by Bp Consulting, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00595543 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.